BEAM.US Beam Therapeutics Inc

Healthcare Biotechnology USA Stocks
23.48 USD
Close of Nov 13, 2026
20.23 38.26
Market cap
USD 2.43B
P/E
-
P/B
2.61x
ROE
-49.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is BEAM.US undervalued?

Graham number

The Graham number of Beam Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Beam Therapeutics Inc fundamental analysis

No fundamental analysis for Beam Therapeutics Inc yet.

Beam Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Beam Therapeutics Inc

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin d…

Full company profile